Thomas Jefferson University

Jefferson Digital Commons
Department of Radiation Oncology Faculty
Papers

Department of Radiation Oncology

6-15-2016

(13)C MRS and LC-MS Flux Analysis of Tumor Intermediary
Metabolism.
Alexander A. Shestov
University of Pennsylvania

Seung-Cheol Lee
University of Pennsylvania

Kavindra Nath
University of Pennsylvania

Lili Guo
University of Pennsylvania

David
Nelson
Follow S.
this
and additional works at: https://jdc.jefferson.edu/radoncfp
University of Pennsylvania
Part of the Medicine and Health Sciences Commons

Let us know how access to this document benefits you
See next page for additional authors

Recommended Citation
Shestov, Alexander A.; Lee, Seung-Cheol; Nath, Kavindra; Guo, Lili; Nelson, David S.; Roman,
Jeffrey C.; Leeper, Dennis B.; Wasik, Mariusz A.; Blair, Ian A.; and Glickson, Jerry D., "(13)C MRS
and LC-MS Flux Analysis of Tumor Intermediary Metabolism." (2016). Department of Radiation
Oncology Faculty Papers. Paper 77.
https://jdc.jefferson.edu/radoncfp/77
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Department of Radiation Oncology Faculty Papers by an authorized administrator of the
Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Authors
Alexander A. Shestov, Seung-Cheol Lee, Kavindra Nath, Lili Guo, David S. Nelson, Jeffrey C. Roman, Dennis
B. Leeper, Mariusz A. Wasik, Ian A. Blair, and Jerry D. Glickson

This article is available at Jefferson Digital Commons: https://jdc.jefferson.edu/radoncfp/77

ORIGINAL RESEARCH
published: 15 June 2016
doi: 10.3389/fonc.2016.00135

13

C MRS and LC–MS Flux Analysis of
Tumor Intermediary Metabolism
Alexander A. Shestov 1 *, Seung-Cheol Lee 1 , Kavindra Nath 1 , Lili Guo 2 , David S. Nelson 1 ,
Jeffrey C. Roman 1 , Dennis B. Leeper 3 , Mariusz A. Wasik 4 , Ian A. Blair 2 and
Jerry D. Glickson 1,5 *
1

Laboratory of Molecular Imaging, Department of Radiology, Perelman School of Medicine, University of Pennsylvania,
Philadelphia, PA, USA, 2 Department of Systems Pharmacology and Translational Therapeutics, Center for Cancer
Pharmacology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA, 3 Department of Radiation
Oncology, Thomas Jefferson University, Philadelphia, PA, USA, 4 Laboratory Medicine, Department of Pathology, Perelman
School of Medicine, University of Pennsylvania, Philadelphia, PA, USA, 5 Department of Biochemistry and Biophysics,
Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

Edited by:
Zaver Bhujwalla,
Johns Hopkins University
School of Medicine, USA
Reviewed by:
Cigdem Soydal,
Ankara University Medical Faculty,
Turkey
Noriko Mori,
Johns Hopkins University, USA
*Correspondence:
Alexander A. Shestov
ashestov@mail.med.upenn.edu;
Jerry D. Glickson
glickson@mail.med.upenn.edu
Specialty section:
This article was submitted to
Cancer Imaging and Diagnosis,
a section of the journal
Frontiers in Oncology
Received: 29 March 2016
Accepted: 23 May 2016
Published: 15 June 2016
Citation:
Shestov AA, Lee SC, Nath K, Guo L,
Nelson DS, Roman JC, Leeper DB,
Wasik MA, Blair IA and Glickson JD
(2016) 13 C MRS and LC–MS Flux
Analysis of Tumor Intermediary
Metabolism.
Front. Oncol. 6:135.
doi: 10.3389/fonc.2016.00135

Frontiers in Oncology | www.frontiersin.org

We present the first validated metabolic network model for analysis of flux through
key pathways of tumor intermediary metabolism, including glycolysis, the oxidative and
non-oxidative arms of the pentose pyrophosphate shunt, the TCA cycle as well as its
anaplerotic pathways, pyruvate–malate shuttling, glutaminolysis, and fatty acid biosynthesis and oxidation. The model that is called Bonded Cumomer Analysis for application
to 13 C magnetic resonance spectroscopy (13 C MRS) data and Fragmented Cumomer
Analysis for mass spectrometric data is a refined and efficient form of isotopomer
analysis that can readily be expanded to incorporate glycogen, phospholipid, and other
pathways thereby encompassing all the key pathways of tumor intermediary metabolism.
Validation was achieved by demonstrating agreement of experimental measurements of
the metabolic rates of oxygen consumption, glucose consumption, lactate production,
and glutamate pool size with independent measurements of these parameters in cultured
human DB-1 melanoma cells. These cumomer models have been applied to studies of
DB-1 melanoma and DLCL2 human diffuse large B-cell lymphoma cells in culture and as
xenografts in nude mice at 9.4 T. The latter studies demonstrate the potential translation of
these methods to in situ studies of human tumor metabolism by MRS with stable 13 C isotopically labeled substrates on instruments operating at high magnetic fields (≥7 T). The
melanoma studies indicate that this tumor line obtains 51% of its ATP by mitochondrial
metabolism and 49% by glycolytic metabolism under both euglycemic (5 mM glucose)
and hyperglycemic conditions (26 mM glucose). While a high level of glutamine uptake
is detected corresponding to ~50% of TCA cycle flux under hyperglycemic conditions,
and ~100% of TCA cycle flux under euglycemic conditions, glutaminolysis flux and its
contributions to ATP synthesis were very small. Studies of human lymphoma cells demonstrated that inhibition of mammalian target of rapamycin (mTOR) signaling produced
changes in flux through the glycolytic, pentose shunt, and TCA cycle pathways that were
evident within 8 h of treatment and increased at 24 and 48 h. Lactate was demonstrated
to be a suitable biomarker of mTOR inhibition that could readily be monitored by 1 H MRS
and perhaps also by FDG-PET and hyperpolarized 13 C MRS methods.
Keywords: metabolic modeling, sensitivity analysis, cancer metabolism, isotopomer, metabolic flux analysis,
isotopolome, 13 C magnetic resonance spectroscopy, 13 C liquid chromatography-mass spectrometry
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with appropriate therapeutic agents whose choice will be at least
partially dictated by metabolic flux analysis of tumors following
administration of appropriate 13 C-labeled substrates. Changes in
tumor metabolism indicated by these labeling experiments will
point to the probable success or failure of drug delivery and will
monitor the effect of these agents on tumor metabolism.
Non-Hodgkin’s lymphoma tumors have served as models
for developing methods for monitoring response to signaltransduction pathway inhibitors (15) as well as response to more
conventional drug combinations, such as RCHOP [Rituximab,
Cyclophosphamide, doxorubicin hydrochloride (Hydroxydaunomycin), vincristine sulfate (Oncovin), and Prednisone (16, 17)].
In this review, we will focus on studies of mammalian target
of rapamycin (mTOR) inhibitors as representative of the former
class of targeted therapeutic agents. Drugs that are inhibitors of
signal-transduction pathways are generally more cytostatic rather
than cytotoxic and usually do not exhibit significant changes in
tumor volume except very late in the course of therapy. For these
drugs, monitoring their effect on tumor metabolism may prove
to be the most efficient approach to detect therapeutic response.
Since 13 C metabolomics/isotopolomic studies are expensive and
labor intensive, it may prove advantageous to identify surrogate
biomarkers of therapeutic response whose metabolism could be
followed by more conventional methods, such as lactate imaging
by 1 H MRS or 1 H chemical exchange of saturation-transfer (1 H
CEST), hyperpolarized 13 C MRS or PET/CT with FDG or other
appropriate metabolic probes. This two-stage approach – utilizing
13
C MRS for initial exploration of overall tumor metabolism and
identification of suitable biomarkers for subsequent follow-up by
1
H MRS or other appropriate method – is a general strategy that
we are proposing for monitoring signal-transduction inhibitors.
The feasibility of achieving this “personalized medicine dream”
or at least the 13 C MRS exploratory phase is already demonstrated through the pioneer work of investigators at the University
of Texas Southwestern, who have monitored the metabolism of
13
C-labeled substrates by ex vivo analysis of surgical specimens
obtained from patients with brain (18) and lung (19) tumors.
Studies of human tumor xenografts in mice detected by 13 C MRS
(see below) will further demonstrate the potential feasibility of
non-invasive monitoring of tumor metabolism. The purpose of
this manuscript is to describe the technical details on how 13 C
isotope kinetics can be monitored and quantitatively analyzed.

INTRODUCTION
Tumor intermediary metabolism provides the energy required
to sustain cancer cells over their entire life span. This energy
is utilized to maintain cation pumps, including the pumps that
eliminate cytotoxic drugs contributing to multi-drug resistance.
It also provides energy for cellular motility during metastasis.
Tumor metabolism also provides key metabolic precursors for
DNA, protein, and lipid synthesis during cellular replication.
Delineation of flux through these critical metabolic pathways provides an invaluable tool, complementary to genomic information,
for cancer diagnosis as well as prediction and early detection of
therapeutic response. Tracing these metabolic pathways was first
accomplished through the use of radioactive isotopic labels, but
monitoring of flux through these pathways has more recently
been achieved by analysis of stable 13 C isotope kinetics labeling
detected with metabolomic tools – magnetic resonance spectroscopy (MRS) and liquid chromatography–mass spectrometry
(LC–MS) – the former providing a potentially non-invasive but
relatively insensitive method for imaging metabolism and the
latter providing a much more sensitive but invasive approach.
Analysis of these dynamic isotopolome (labeled metabolome)
data used to require solution of hundreds of differential equations
that could only be accomplished with the help of supercomputers
(1), but today can be readily accomplished with laptop computers
virtually in real time. This problem has been solved for normal
organs, such as the heart (1–6), brain (7–9), and liver (10–12); our
goal here is to describe the first validated solution of the problem
for tumors.
We present data on human DB-1 melanoma and models of
various non-Hodgkin’s lymphomas (NHLs). DB-1 melanoma has
served as the principal tumor model on which this technology
has been developed and validated (13, 14). This technology has
been applied to isolated perfused tumor cells grown ex vivo as
monolayers on solid microcarrier beads in a bioreactor system
or in flasks and to in vivo xenografts in mice. Isotope exchange
has been monitored non-invasively in vivo or in intact cells by
13
C MRS and invasively by LC–MS following ex vivo extraction.
The NHL models have been examined by similar methods except
that because they are anchorage independent, they had to be
immobilized by encapsulation in agarose beads or studied in batch
suspension culture. Encapsulation of cells in agarose or alginate
beads invariably introduces heterogeneity in the cellular microenvironment, a problem that can be overcome by growth in batch
culture from which aliquots are isolated for periodic analysis.
The goal is to lay the groundwork for performing these measurements non-invasively on human patients who will be monitored
in high-field (≥7 T) spectrometers before and following treatment

BACKGROUND
Types of 13 C MRS Experiments

Following administration of 13 C-labeled substrates, one can monitor the time course of distribution of the isotopic label among the
various metabolites of the substrate either directly by 13 C MRS
or indirectly through 1 H MRS of the protons directly bonded
to the isotopically labeled carbon atoms. These methods have
been extensively reviewed by de Graaf et al. (20) and will not be
considered further here except to note their key advantages and
limitations. Direct detection offers the advantage of simultaneously monitoring all the sites of isotopic substitution, but signal
intensity will depend on the detection coil, the method used for
proton decoupling as well as on the pulse sequence that is used

Abbreviations: AA, amino acids; ASCT2, alanine-serine-cysteine (GLN) transporter 2; BC, Bonded Cumomer; CEST, chemical exchange saturation-transfer;
CMR, cellular metabolic rate; CMRatp, ATP production rate; CMRlac, Lactate
production rate; FA, fatty acid; GLUT, glucose transporter; h, hours; IDH, isocitrate
dehydrogenase; MCT, monocarboxylic acid transporter; MID, mass-isotopomer
distribution; MRO2 , O2 consumption rate; oxphos, oxidative phosphorylation; PPP,
pentose phosphate pathway; P/O, phosphate to oxygen ratio; RC, reductive carboxylation; SGOC, serine glycine one carbon metabolism; TCA cycle, tricarboxylic acid
cycle.
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for 13 C excitation. Broadband decoupling, the method that we
have employed, will simultaneously decouple all the protons and
will produce nuclear Overhauser enhancements (NOE) that will
depend on relaxation times, the fraction of the relaxation occurring through dipolar mechanisms and the broadband decoupling
technique (e.g., MLEV and WALTZ). There will be differences
in signal enhancement, and these will have to be calibrated. For
in vivo applications, the NOEs vary between 1.3 and 2.9 for protonated carbons, and are 1.0 for unprotonated carbons or carbons
that relax by non-dipolar mechanisms. Alternatively, one could
use dynamic polarization-transfer excitation for direct 13 C excitation (21, 22); this method requires quantum mechanical density
matrix or product-operator analysis for quantitative interpretation, which is beyond the scope of this manuscript. In general, the
direct excitation methods, delineated as 13 C-{1 H}, are less sensitive than the indirect detection techniques, 1 H-{13 C}, by which the
protons directly bonded to the isotopically labeled carbon atoms
are monitored with the 13 C magnetization being manipulated
either by simple subtraction of multiple experiments, by multiple
quantum coherence transfer or by J-difference pulse sequences
that depend on spin–spin coupling (20). Another key consideration in these experiments is the issue of power deposition or
sample heating, which becomes limiting in the inverse-detection
techniques when broadband decoupling of carbon resonances is
applied and also depends on coil design and various other factors.
While we note the potential signal enhancing possibilities that
can be achieved with indirect detection, most investigators, and
our group included, utilize simple direct 13 C-{1 H} detection with
broadband decoupling at least as a starting point for MRS studies
of 13 C isotope exchange kinetics.

ports of the Langendorff perfusion apparatus; MRS and MRO2
data acquisition were performed directly in the magnet on the
beating heart, and the mathematical fitting was performed with
a simple laptop computer. The results demonstrated that the original model proposed by Chance et al. (1) consistently predicted
MRO2 values that were significantly below the experimentally
measured rates. The error was attributed to the absence of the
shuttles in the TCA cycle model; inclusion of the malate-aspartate
and glycerophosphate shuttles in the model led to perfect agreement between experimental and model-predicted data. We believe
that this was the first validated isotope enrichment model.
In 1994, Sherry and Malloy and coworkers at Dallas Southwestern (23) introduced a considerably more efficient method,
isotopomer analysis, which took into account multiple sites of
isotope labeling and substantially simplified the mathematics of
analysis of the kinetics of isotope labeling. This method was first
employed to measure relative rates of anaplerotic vs. TCA cycle
flux in the heart and was later extended to monitor more extensive
metabolic pathways in various organs, including liver (24–30) and
brain (31–42). Comparison of experimental and predicted MRO2
values validated the cardiac isotopomer analysis model of Jeffrey
et al. (3).
The motivation for developing additional theoretical framework to study the fluxome (13) came from the challenges of
modern metabolic flux analysis. The details of flux analysis based
on cumomers were introduced in Ref. (43). Alternative cumomer
methods, such as elementary metabolite units (44), aim to minimize the dimension of variables space and to reduce the cost of
computation.
More recently, Shestov and colleagues introduced bonded
cumomer analysis at the University of Minnesota, where research
focused primarily on the brain (45), and later at the University
of Pennsylvania, where tumors were the central focus of research
(14, 46). Cumomer analysis is a more efficient method of generating the various isotopomer equations. Two variants of the
cumomer method are still under development, bonded cumomer
analysis, which applies to the analysis of 13 C MRS data (14, 46),
and fragmented cumomer analysis (47–49) that analyzes LC–MS
data. The relative efficiency of the cumomer methods is perhaps
best illustrated by the fact that the original study of TCA cycle
metabolism of the heart using a model that lacked inclusion of
the two shuttles required about 325 differential equations to solve,
whereas the current bonded cumomer model describing about 10
pathways of tumor intermediary metabolism including the TCA
cycle and the pentose phosphate pathway are accomplished with
~210 differential equations that can be solved virtually in real time
with an ordinary laptop computer.

Metabolic Flux-Analysis Models
Metabolic flux-analysis dates back to the classic study published
in 1983 by Chance, Seeholtzer, Kobayashi, and Williamson at the
University of Pennsylvania and University College London, on
flux through the tricarboxylic acid cycle (TCA cycle) in Langendorff perfused rat hearts (1). These investigators sacrificed
large numbers of rats, excised their hearts, mounted them in a
Langendorff retrograde perfusion apparatus, perfused the hearts
with various 13 C enriched substrates ([3-13 C] pyruvate or [213
C] acetate), freeze clamped the hearts at various time points,
extracted the water soluble metabolites with perchloric acid, and
analyzed the extracts with direct 13 C-{1H} MRS to measure the
time course of isotopic labeling of glutamate, alanine, and aspartate. The data were fit by least-squares analysis to an idealized TCA
cycle model consisting of oxaloacetate in equilibrium with aspartate, citrate, α-ketoglutarate, and reactions involving glutamate,
succinate, and malate. The analysis required about 325 differential
equations that were solved with the aid of a Cray supercomputer.
The model fit estimates of isotope enrichment of carbon atoms in
glutamate and aspartate, and calculated the rate of TCA cycling,
but did not attempt to validate this rate. This was accomplished
later by Chatham et al. (2), who calculated the metabolic rate
of oxygen consumption (MRO2 ) from the rate of production of
reducing equivalents assuming that the system was at equilibrium.
They compared the calculated rate with the experimental rate
measured with oxygen electrodes placed at the inlet and outlet

Frontiers in Oncology | www.frontiersin.org

Types of 13 C Metabolic Models
Metabolic isotope kinetic models can be subdivided into steadystate and dynamic models, with the former analyzing measurements of isotope distribution after isotopic steady state has been
established and the latter requiring a complete kinetic study.
The kinetic analysis is much more demanding and is yet to be
achieved in the clinical arena (18, 19). Steady-state measurements
can only measure relative rates, normalized to some standard
reference rate, such as TCA cycle flux, whereas the true kinetic
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measurements yield absolute fluxes through individual metabolic
pathways. Steady-state measurements can often be made on surgically excised or biopsy derived specimens, and in the case of
MRS measurements, their signal-to-noise ratio can be enhanced
by long-term signal averaging, but kinetic measurements have
to be performed non-invasively in real time by MRS studies of
isolated perfused cells grown in a suitable bioreactor contained in
the NMR spectrometer or by non-invasive MRS measurements on
living animals or humans. Alternatively, one can perform kinetic
experiments by periodically sampling cells or extracts from a living host or from a bioreactor system. Both types of measurements
may eventually prove useful in the clinic, but the hope is that highfield MRS will for the first time enable totally non-invasive studies
of human subjects. Dynamic nuclear polarization already enables
performance of true kinetic measurements in living animals and
even in humans, but to date this has not been accomplished at
normal in vivo concentrations; instead, ex vivo injections of much
higher concentrations of isotopically labeled hyperpolarized specimens, most often labeled pyruvate have been utilized and monitored within about a minute in real time. The relationship of such
studies to actual in vivo metabolism is the subject of considerable
controversy and debate that requires further investigation. Even if
such methods distort in vivo metabolism, they might still be useful
for clinical diagnosis and monitoring of disease and therapy.

The following metabolic pathways are included in the network:
glycolysis, TCA cycle, α-ketoglutarate–glutamate, and oxaloacetate–aspartate exchange through the malate-aspartate shuttle,
anaplerosis through (a) pyruvate carboxylase (PC) activity, (b) at
the succinyl-CoA level, and (c) glutaminolysis through mitochondrial glutaminase (GLS and GLS2), pyruvate recycling through
cytosolic (ME1) and mitochondrial malic enzymes (ME2 + ME3),
lactate dehydrogenase (LDH) activity, and transport processes.
Oxidative and non-oxidative branches of the pentose phosphate
pathway (PPP) fluxes were included in the modeling analysis as
well as de novo lipogenesis and fatty acid (FA) oxidation.
In order to permit access of pyruvate to the pyruvate dehydrogenase complex (PDH) complex for conversion to acetyl-CoA and
incorporation into the TCA cycle, we have included the mitochondrial pyruvate carrier (MPC), which was recently identified in all
mammalian cells (54–56). Pyruvate is also linked to the TCA cycle
via PC. The cytosolic compartment with direct links through the
mitochondria to the TCA cycle also contains citrate, glutamate,
and malate. As noted above, the mitochondrial compartment contains the complete TCA cycle with links to the cytosol for citrate
and malate. α-Ketoglutarate is linked to glutamate via glutamate
dehydrogenase (GLUD) and two aminotransferases, aspartate
aminotransferase (GOT), and alanine aminotransferase (GPT).
In order to fit 13 C time courses of labeled lactate, glutamate
and FAs to determine the corresponding metabolic fluxes and the
transport parameter for bidirectional lactate transport through the
cell membrane, we constructed a BC dynamic model adapted to
perfusion bioreactor experiments. In the model, the perfused [1,613
C2 ] glucose and glutamine (labeled in some experiments, see
below) are transported from the extracellular medium to the DB1 cells. Reversible non-steady-state Michaelis–Menten facilitative
transport kinetics are assumed to occur through glucose (GLUT
family) or glutamine (ASCT2) transporters:
(
)
Mei
Mi
Jmax
tr − Ktr
tr
K
mi
mi
Jtri =
,
(1)
1 + KMtrei + KMtri

Mass Spectrometric Studies of Tumor
Metabolism
For dynamic isotopic labeling, DB-1 cells were cultured in
glutamine-free DMEM containing 2 mM [U-13 C5 ,15 N2 ] glutamine supplemented with 10% fetal bovine serum. After 0,
0.5, 1, 2, 4, and 6 h of incubation, medium was aspirated and
cells were snap frozen on dry ice. For comparing euglycemic
vs. hyperglycemia conditions, cells were labeled with glutaminefree DMEM containing 2 mM [U-13 C5 ,15 N2 ] glutamine and 5 mM
glucose or 25 mM glucose for 8 h. LC–MS analysis of isotopic
labeled metabolites was performed as previously described (47).

mi

The Metabolic Network Model

where is the net transport flux for boundary species i between
media and cytosol or cytosol and mitochondria; Mei is the extracellular concentration for species i, Jmax
tr is the maximal transport
rate, and Ktrmi is the Michaelis–Menten constant for transport.
Labeled lactate from the cell is transported into the medium while
obeying Michaelis–Menten kinetics through the monocarboxylic
acid transporter (MCT family). Facilitated media-cell transport is
assumed for glucose, lactate, and glutamine.
Two types of mass balance equations for chemical and isotope
variables were expressed mathematically using the mass balance
equation for the total metabolite concentration in the medium,
cytosol, and mitochondria:

We have utilized a novel three-compartment metabolic network model with the bionetwork schematically depicted in
Figure 1 to calculate fluxes through key pathways of tumor energy
metabolism from 13 C isotopic labeling data. This model includes
the perfusion medium, cytosolic and mitochondrial compartments interconnected by various transporters, carriers, and
enzymes that span adjacent compartments. The model is applicable to bioreactor systems and to in vivo data. Glucose (GLUT),
monocarboxylic acid (MCT), and glutamine (GLN) transporters
to the cytosolic compartment are included in the cytosolic membrane. Tumors generally express GLUT1 and GLUT3, but only
GLUT1 is currently included in the model; similarly DB-1 contains MCT1 and MCT4 in approximately equal proportions (50),
but since the KM of MCT1 is approximately one-fifth that of MCT4
(51–53), we have only included MCT1. Because of the critical role
of glutamine in tumor energetics and metabolism, we have also
included the GLN transporter (ASCT2). This model can readily
be extended to incorporate other isoforms of MCT and GLUT as
well as transporters for other amino acids (AAs) and metabolites.

Frontiers in Oncology | www.frontiersin.org

mi

Jtri

∑ pj pj ∑ uk uk
dMi
= Jtri +
νi Fi −
ν i Fi ,
dt
j

(2)

k

where Mi is the intracellular concentration of the i species, Jtri is
the net transport flux for boundary species i between media and
pj
cytosol or cytosol and mitochondria, Fi and Fuk
i are the normalized reaction fluxes that produce (j) or utilize (k) cellular species i,
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FIGURE 1 | Studied melanoma bionetwork: glycolysis, PPP, TCA cycle, α -ketoglutarate-glutamate, and oxaloacetate-aspartate exchange through
the malate-aspartate shuttle, anaplerosis through (a) pyruvate carboxylase activity, (b) succinyl-CoA, and (c) glutaminolysis through mitochondrial
glutaminases (GLS and GLS2); pyruvate recycling through cytosolic (ME1) and mitochondrial malic enzymes (ME2), lactate dehydrogenase activity,
de novo fatty acid synthesis, and transport processes. Metabolic flux map and energy metabolism with predicted oxygen consumption rate MRO2 in the
human melanoma DB1 bionetwork at hyperglycemia and normoxia. Numbers indicate fluxes in millimoles per liter-cell per hour. See Table 1 for definitions and values
of the derived fluxes.

pj

unlabeled carbons, isotopomer models take full advantage of the
biochemical information that can be obtained from the NMR
spectra, yielding a total of 2N − 1 independent variables for a
molecule with N different carbon atoms. Because not all possible
isotopomers are detectable by NMR, a model including all possible
isotopomers would be unnecessarily complex. The concept of
bonded cumomers leads to a reduced number of equations as well
as a more simple derivation of these equations compared to a
model, including all possible istopomers, while retaining all the
NMR measureable isotopomer information.
Let M{i} denote the isotopomer of a metabolite M, where {i} is a
set of integers i1 , i2 ,. . ., in indicating the positions of all the labeled
carbons. We refer to m{i} as the isotopomer fraction [M{i} ]/[M] of
molecules M labeled exactly at positions i1 , i2 . . ., in . A cumulative
isotopomer fraction (or cumomer fraction), noted as pM{i} is by
definition, the sum of isotopomer fractions for all isotopomers
labeled at least at positions i1 , i2 . . ., in , whatever the label at the
other positions. We refer to the size n of the set {i} as the order of

and νi and νuk
i are the corresponding stoichiometric coefficients.
The following general dynamic mass balance equations were used
to describe the extracellular boundary metabolites in the medium:
dMe
= rie × Jtri ,
dt

(3)

where extracellular species concentration is Me , and rie is the ratio
of cell volume to media volume. We also included an additional
term for the medium flow rate. Note that we do not assume here
that media boundary metabolites are at constant concentration.

Bonded Cumomer Analysis
One can monitor flux through the biochemical network model
by measuring changes in isotopic enrichment of individual carbons in a molecule containing N carbon atoms. This yields a
total of N-independent time-courses or steady-state values. However, by considering all the different combinations of labeled and
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the p-function. For example, assuming that M has a total of four
carbons, the second order p-function pM{1,3} can be expressed as:

glycolytic flux CMRlac and others, we also calculated other
fluxes and parameters, including the Warburg parameter (ratio
of flux from pyruvate to lactate vs. pyruvate to the MPC).
Using the Runge–Kutta fourth-order procedure for stiff systems in terms of Bonded Cumomers, we solved these differential equations to obtain time courses for all possible fine
structure 13 C multiplets of glutamate, glutamine, and aspartate.
Minimization of the cost function was performed using Broyden–Fletcher–Goldfarb–Shanno or Simplex algorithms. By verifying that goodness-of-fit values were close to expected theoretical
values, we confirmed proper mean-square convergence. Monte
Carlo simulations with experimental noise levels were used to
calculate parameter errors (58). All numerical procedures were
carried out in Matlab (Mathworks, Natick, MA, USA).
Liquid chromatography-mass spectrometry data without
detailed flux analysis were utilized to compare fluxes under
different conditions (e.g., hyperglycemia vs. euglycemia) since no
statistically significant change was observed between the different
medium glucose concentrations.

pM{1,3} = m{1,3} + m{1,2,3} + m{1,3,4} + m{1,2,3,4} (4)
For example, the cumomer fraction pM{1,3} for cumomer M{1,3}
is the probability that both the first and third carbon atoms of
this molecule are labeled. Shestov et al. (45) have presented a
complete exposition of the bonded cumomer formalism. Here, we
will present examples of how this formalism can be utilized to
efficiently monitor flux through the various metabolic pathways
in Figure 1 in various types of perfused cells and in xenografts
of these tumor cells in immunosuppressed mice. These examples
illustrate the type of information that can be obtained from similar
dynamic studies performed on human tumors in situ or from
extracts of biopsy or surgically excised freeze-clamped specimens
of these tumors measured at isotopic steady state.
Isotopomer dynamics of this system together with the initial
metabolome state vector M0 ∈ RN and fluxome Fo ∈ RM (subscript “0” refers to baseline steady-state values and reaction rates)
are formulated as an initial value problem for ordinary differential
equations (ODE) in terms of Bonded Cumomer fractions as the
state variables. Metabolite 13 C cumomer mass balance for parallel
monomolecular reactions was expressed in the form:
∑
dπ(i)
=
Fj π σj(i) −
[M]
dt
j

(
∑

Metabolic Isotopomer Control Analysis for
Bonded Cumomer Models
Metabolic control analysis (MCA) was originally proposed to
quantify sensitivity – i.e., to measure the effect of changes in
any parameter of a system on the other variables in that system.
This approach was developed independently by two groups in the
1970s (59, 60) and has been limited to systems at steady state.
In this approach, the sensitivity of changes in variables, such as
metabolite concentrations due to changes in other parameters is
quantified by control coefficients. Metabolic control coefficients
are used for comparison of many parameters that span several
orders of magnitude. A control coefficient is defined as the relative
change in the variable per relative change in the parameter, when
infinitesimal changes are introduced:

)
Fk

π(i) ,

(5)

k

where metabolite M with pool size [M] is downstream of metabolites Sj . While π(i) and π σj(i) represent the ith cumomer fraction of metabolite M and metabolite Sj (i Bonded Cumomer),
respectively. The total outflux ΣFk balances influx ΣFj .
Shestov and coworkers (45) have described how isotopomer
balance equations have been derived for every metabolite Bonded
Cumomer of orders 1, 2, 3 (e.g., glutamate, glutamine, aspartate).
This resulted in a set of ~210 differential equations with fine
structure multiplets completely described by each metabolite’s
Bonded Cumomers of order 1, 2, and 3. Wiechert et al. (43) first
proposed the term cumomer, and the concept of cumomer was
used by Muzykantov and Shestov (57) in early studies. There are
connection matrices between the “Bonded Cumomer” π vectors
(which reflect subsets of metabolite isotopomers) and the vectors of “fine structure” multiplets of 13 C NMR spectra (singlets,
doublets, triplets, and quartets of 13 C-labeled metabolite). Using
matrix connection equations, one derives kinetic equations in the
form of fine-structure spectroscopic-defined NMR data.
The fitted time-courses for [1,6-13 C2 ] glucose perfusion were:
Glu4Tot (Tot-total), Glu4s, Glu4d34, Glu3Tot, Glu3d, Glu2Tot,
Glu2s, Lac3Tot, and acyl methylene (–(CH2 )n –) resonance, for
a total of nine curves from which we determined the following
free fluxes: melanoma TCA cycle FTCA , PC FPC , exchange between
glutamate and α-ketoglutarate FX , anaplerotic exchange and net
flux at the level of SucCoA, FANA , mitochondrial malic enzyme
(ME2 + ME3) activity, de novo FA production, glutaminolysis,
aspartate efflux, and three other parameters – Michaelis–Menten
LAC
lactate transport VLAC
max and Km and total cellular lactate concentration. Based on flux balance analysis including non-oxidative
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(
CRp =

∂R/R
∂p/p

(

)
=
ss

∂lnR
∂lnp

)
,

(6)

ss

where p is varied parameter and R is a system response, e.g.,
concentration or flux; the subscript ss indicates steady state. Sensitivity analysis measures the robustness of the metabolic model and
network topology to variations in parameter values. The robust
parameters with greatest influence on model simulation can help
to identify critical fluxes and pathways. These fluxes also have
less experimental error. Here, we extend the MCA technique to
dynamic metabolic flux analysis in which the behavior of interest
occurs in the temporal responses. First, we introduce the dynamic
isotopomer control coefficient or the sensitivity function:
(
ICCik =

∂π(i) /π(i)
∂Fk /Fk

)
,

(7)

where π(i) represents the ith cumomer fraction of metabolite M,
and Fk is a certain parameter, such as a flux. By introducing these
variables, isotopomer sensitivity equations can be derived by differentiating dynamic bonded cumomer balance equations (Eq. 5)
with respect to identified fluxes or other parameters that yield
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the corresponding initial value Cauchy problem for non-linear
ODE. The dynamic sensitivity equations determine the time evolution of isotopomer control coefficients. These consist of a large
number of equations that must be solved simultaneously with the
initial system (1) resulting in double the number of differential
equations. These characteristics of the output sensitivity matrix
with respect to the flux vector F and other parameters provide
a framework for analysis of isotopomer model robustness. By
simulating the dynamic time course of sensitivity functions, one
identifies the fluxes most sensitive to a particular bonded cumomer of a metabolite and 13 C fine structure multiplet. Figure 2A
displays calculated values of those dynamic isotopomer control
coefficients (or relative sensitivity functions).
We also computed the sensitivity of the mean squared difference between experimental and corresponding model output (i.e.,
error) to finite changes in parameter values. The sensitivity to each
parameter was calculated as the relative change in mean squared
error (MSE) due to 5% change in the given parameter value:
Si =

max |(E (pi ± 0.05pi ) − E (pi ))|
,
0.05pi
pi ∗ E (pi )

results in a significant change in the simulated curves and in the
MSE E.
Figure 2B shows calculated MSE sensitivities for several free
fitted fluxes.

Applications of Metabolomics to
Melanoma and Lymphoma
To illustrate the application of these techniques to studies of
human cancer, we will describe studies of human melanoma
models grown in culture, as perfused tumor cells grown on
solid microcarrier beads and as xenografts in immunosuppressed
mice. The cell studies will be utilized to validate the bonded
cumomer model and to estimate the contributions of glycolytic
metabolism and mitochondrial metabolism to ATP production
under hyperglycemic (26 mM) and euglycemic (5 mM) conditions. Effects of euglycemia and hyperglycemia on glutamine
metabolism, flux through the pentose shunt and FA metabolic
pathways will also be evaluated using both 13 C MRS and bonded
cumomer analysis as well as LC–MS and fragmented cumomer
analysis.
To demonstrate how 13 C MRS and LC–MS can be used to detect
response to signal-transduction inhibitors, we will present data
on the effect of rapamycin, a well known inhibitor of the mTOR
pathway, on DLCL2 human diffuse large B-cell NHL cells grown
in culture as perfused cells immobilized by encasement in agarose
beads and as xenografts in immunosuppressed mice. We will

(8)

where E represents the minimum mean squared difference
between model simulation and experimental data. These sensitivity values represent the degree to which the theoretical curves
are sensitive to the value of individual parameters. High values of
the sensitivity parameter Si indicate that changing a parameter pi

FIGURE 2 | The dynamic multiplet control coefficients and sensitivity analysis. (A) In the left panel, the dynamic multiplet control coefficients are shown with
respect to glutaminolysis flux for the glutamate-C4 total and doublet C4d34 and singlet C4s multiplets and the glutamate-C3 and glutamate-C2 total and their
multiplets (right panel) during perfusion with medium containing [1,6-13 C2 ] glucose and unlabeled glutamine. Data show the time courses of normalized multiplet
sensitivities to variation of the glutaminolysis flux. For simulation, the conditions were chosen to optimize extracted fluxes, while glutaminolysis flux was set at 5% of
the TCA cycle flux. The glutamate doublet 4d34 is the most sensitive glutamate multiplet to measure glutaminolysis net flux during the first ~1.5 h, and afterwards the
4s singlet becomes more sensitive. The data in the right panel demonstrate the superior sensitivity of the glutamate 3d doublet at the beginning and glutamate 2s
singlet after ~1.5 h. (B) Total relative mean squared error (MSE) sensitivity function output during perfusion with medium containing [1,6-13C2] glucose and unlabeled
glutamine with respect to free fitted fluxes. Upper panel shows the sensitivities to the TCA cycle, anaplerotic net flux at the level of SucCoA and mitochondrial malic
enzyme activities; and lower panel shows MSE sensitivities to the pyruvate carboxylase (pc), exchange flux α-Kg ↔ glu (x), exchange flux at the level of SucCoA (ana)
and glutaminolysis flux (gls). Note also the significant sensitivities for the fluxes in the upper panel and higher sensitivity for glutaminolysis compared to other fluxes in
the lower panel.
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demonstrate that response to this inhibitor can also be monitored
by 1 H MRS lactate imaging in cells and in xenografts. Ultimately,
the goal will be to translate these methods into the clinic to manage
human NHL patients. Preliminary studies leading to this approach
have been published (15).

tube permitting the oxygen consumption rate of the culture to be
monitored continuously from the decrease in pO2 . A pH probe
(Mettler-Toledo, Columbus, OH, USA) was inserted downstream
of the outlet oxygen probe. Adjustment of the level of CO2 in
the gas-exchange module was used to modify/maintain the pH of
the medium. The temperature of the medium entering the NMR
tube was monitored with a thermocouple at the exit port of the
perfusion chamber and was fine-tuned with a microstat-controller
and an electrical resistance heater to 37.0 ± 0.2°C. The glucose
concentration in the recirculating medium was maintained at a
constant level (clamped) by continuously feeding fresh medium
typically at a flow rate of 24 ml/h and removing depleted medium
from a recirculation bottle while maintaining the total volume of
recirculating medium at 120 ml. During 13 C experiments, 32 mM
[1,6-13 C2 ] glucose was fed into the system, and the recirculating
glucose level was clamped at 26 mM by adjusting the feed rate.
13
C NMR spectra were acquired with standard 1 H decoupled NOE 13 C acquisition on a 9.4 T/89 mm vertical bore Varian
spectrometer (Varian Inc., Palo Alto, CA, USA) with acquisition
parameters: 60° pulse angle, 1.2 s repetition rate, 25,000 Hz spectral width, 16,384 points, and 750 transients per spectrum. Freeinduction decays were apodized by exponential multiplication
(2 Hz) for signal to noise enhancement and peak areas were measured with Nuts NMR (Acorn NMR, Fremont, CA, USA) software.
The number of cells in the NMR tube was determined from the
total NTP level measured by 31 P NMR as described previously
(64) using the following spectral parameters: 60° pulse angle, 1 s
repetition rate, 15,000 Hz, 1,200 transients.
Melanoma cells were initially studied under normoxic hyperglycemic (26 mM glucose) conditions to enhance lactic acidosis
(65, 66) and subsequently under normoxic euglycemia (5 mM
glucose) to more closely simulate in vivo conditions. The effect
of these changes in glucose concentration on flux through various
pathways of tumor metabolism was determined over a ~6 h time
course during which the kinetics of labeling of lactate, glutamate
and other metabolites was monitored. The estimated TCA cycle
flux was compared to the oxygen consumption flux to test the
accuracy of the calculations.

MATERIALS AND METHODS
Cell Culture
The human DB-1 melanoma cell line was derived by David Berd
from a lymph node metastasis of one of his patients (Thomas Jefferson University Hospital, Philadelphia, PA, USA) before administration of any treatment. Cells were cultured from the tumor
and cryopreserved after the 16th passage. Monoclonal antibodies
were used to confirm cell surface antigens (61). DB-1 cells were
grown as monolayers for routine culture at 37°C in 5% CO2 in αMEM medium supplemented with 10% fetal bovine serum, 2 mM
glutamine, 26 mM glucose, and 1% (v/v) non-essential AAs and
10 mM HEPES buffer. In tissue culture flasks, the doubling time
was 48 h (50). The V600E BRAF mutation is expressed by the
DB-1 cells.

Cell Perfusion and NMR Spectroscopy
For NMR studies of perfused tumor cells, DB-1 cells were cultured
in DMEM with 1% non-essential AAs (Invitrogen, Grand Island,
NY, USA), 10% fetal bovine serum, 10 mM HEPES, 4 mM glutamine, and 26 mM glucose (complete DMEM). Approximately
5 × 108 cells were grown on the surface of non-porous microcarriers that had a mean diameter of 170 microns (Solohill, Ann Arbor,
MI, USA). These microcarriers were coated with either collagen
or ProNectinF® to enhance cell attachment and proliferation and
tightly packed inside a 20 mm NMR tube in which they were
perfused continuously in the open bioreactor system. Mancuso
et al. (62) have published a detailed description of the perfusion
system, including flow rates, cell adhesion procedures, etc.
The method of Bental et al. (63) was used to immobilize lymphoma cells (DLCL2) by encapsulation into agarose beads. In
brief, we thoroughly mixed 1.5 ml of ~5 × 108 cells in culture
medium with an equal volume of the low-temperature-gelling
agarose at 37°C and magnetically stirred the mixture after addition
of 3 ml paraffin oil at 37°C generating the cell-encapsulated spherical beads with 100–200 μm diameters. The beads were cooled by
continuous stirring, and the oil was removed by centrifugation.
The encapsulated cells were then loaded into a 10 mm NMR tube
connected to the perfusion system.
Medium was circulated through the microcarriers or agarose
gel at a flow rate of 12 ml/min with a peristaltic pump (Masterflex,
Cole Parmer, Chicago, IL, USA). A gas-exchange module consisting of a silicone membrane (thin-wall silicone tubing) was situated
before the perfusion chamber along the medium flow path for
removal of carbon dioxide and addition of oxygen. The oxygen
level was measured continuously with a polarographic oxygen
probe (Mettler-Toledo, Columbus, OH, USA) situated at the inlet
port to the perfusion chamber and maintained at a steady-state
pressure near air saturation. The medium was then warmed to
40°C, and a second polarographic oxygen probe was used to
detect the oxygen level of the medium coming out of the NMR
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In vivo animal studies
Immunosuppressed mice were used for in vivo studies. Tumors
were developed by subcutaneous implantation of tumor cells to
the flanks of nude mice. NMR studies on mice were performed
using a home-built 13 C/1 H dual-tuned probe at 9.4 T (Varian Inc.).
All animal studies were approved by the Institutional Animal Care
and Use Committee (IACUC) of the University of Pennsylvania,
and performed in accordance with its regulatory standards.

Statistical Analysis
Student’s t-test was used to calculate p-values. P-values <0.05 were
considered significant.

RESULTS AND DISCUSSION
Melanoma Studies
Determination of the relative levels of glycolytic and oxidative metabolism of specific tumors plays an important role in
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development of strategies for treating neoplasms and for choosing appropriate methods to detect tumor response to specific
therapies. Development of a non-invasive method for quantifying the fraction of ATP production by tumors that occurs by
glycolytic and mitochondrial metabolism would be very useful
in the management of cancer patients and tailor-fitting of therapeutic regimens to their individual needs. In addition, various
other pathways of tumor metabolism play critical roles in tumor
proliferation by providing essential precursors for cell replication.
We, therefore, sought to develop a method for quantitating tumor
intermediary metabolism in cells with appropriate extension to
animal tumor models and eventually to human cancer patients.

C4 (producing a singlet peak) gradually slowed and approached
steady state after approximately 6 h. The level of coupled glutamate
labeled at both C3 and C4 continued to increase steadily throughout the experiment. Labeling of the glutamate-C3 resonance at
28.8 ppm is displayed in Figures 4A,B. 13 C labeling of this carbon
increased linearly but did not reach saturation. Approximately,
two-thirds of the C3 glutamate carbon was coupled (predominantly to glutamate-C4). Within 1 h, glutamate-C2 labeling was
detected (Figures 4A,B). However, only a singlet was observed
for the first 3 h, unlike glutamate-C3 which exhibited multiplet
structure. Subsequently, a doublet appeared due to the presence
of glutamate-C2,3 labeling after carbon 1 was removed from
glutamate-C3,4 during the third turn of the TCA cycle (1).
Labeling was also observed in long chain FAs at approximately
30 ppm, indicating that DB-1 melanoma cells produce lipid de
novo from glucose (see Figure 4D), consistent with results for
other cancer cell lines grown in culture (67). Low levels of labeling
of aspartate-C2 and C3 were also observed. Labeling of alanine
was not detected, probably due to the low total concentration of
this AA; this result is unusual since most cancer cell lines produce 13 C-labeled alanine from glucose (62, 67). Resonances were
observed at approximately 65 ppm, a spectral region associated
with the glycerol backbone of phospholipids in triglycerides as
well as other glycolytic intermediates.

Metabolic Fate of [1,6-13 C2 ] Glucose in
DB-1 Cells
The entire metabolic network that is included in the current
analysis is depicted in Figure 1. Figures 3A and 4 summarized
13
C labeling kinetics of DB-1 melanoma cells grown at a constant
glucose level of 26 mM. Dynamic 13 C NMR spectra obtained
during the experiment appear in Figure 3A. We detected resonances of C3 lactate, C2, C3, and C4 glutamate, C2 and C3 of
aspartate, and fatty acyl carbons. Under hyperglycemic conditions
(26 mM glucose), lactate labeled at C3 (20.9 ppm) appeared in
the spectrum within the first few minutes (Figures 3A and 4C).
Levels of this metabolite increased throughout the experiment
but did not reach saturation. Lactate resonance intensity was the
combined result of the biological rate of lactate formation and the
rates of washout of lactate due to the continuous addition of fresh
medium and withdrawal of spent medium from the perfusion system. Fifteen minutes after introduction of labeled glucose, isotopic
13
C incorporation in C4 of glutamate (34.3 ppm) was detected;
Figure 4A shows the full-time course for labeling results for this
resonance. The concentration of C4-labeled glutamate increased
linearly for ~1 h. Satellites were subsequently detected indicating the presence of 13 C-13 C coupling between glutamate-C4 and
glutamate-C3 (1). The rate of labeling of glutamate exclusively on

Quantifying Bionetwork Fluxes

We utilized Bonded Cumomer analysis to fit 13 C NMR DB-1
melanoma data acquired during continuous perfusion of cells
with [1,6-13 C2 ] glucose in the bioreactor system. Isotopomer
time course data were converted to 13 C-metabolite concentration
curves (Figure 4). Only those multiplets with end-point concentrations >0.5 mM were used in the fitting procedure in order to
minimize the bias introduced by using multiplets with low signal
to noise ratio. Since the noise level of the remaining experimental
multiplets was expected to be high (not shown), these resonances
were used only as reference points for visually examining the fit
predicted for low intensity curves to experimental data but not

FIGURE 3 | Time course 13 C NMR spectra of perfused DB-1 melanoma cells in a bioreactor (A), and of a DB-1 melanoma xenograft (B). Glu, glutamate;
Lac, lactate; Glc, glucose; std, ethanol in capillary; FA, –CH2 – groups in long chain fatty acids. [1,6-13 C2 ] glucose was used as the substrate for 13 C-labeling.
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FIGURE 4 | Time courses for labeling of glutamate, lactate, and fatty acyl resonances during perfusion with medium containing [1,6-13 C2 ] glucose
and unlabeled glutamine. (A) Time course fits for labeling of glutamate (indicated with “fit” ending) at positions 4, 3, and 2. Glu4, 13 C at glutamate-C4; Glu4s,
singlet at glutamate-C4; Glu4d34, doublet at glutamate-C4. Glu2, 13C enrichment at glutamate-C2; Glu3, 13C at glutamate-C3. “fit” ending stands for the model fit
and no-ending reflects experimental values. (B) Time courses for labeling glutamate at positions 2 and 3. Fitted curves labeled with ending “fit” are Glu2 and Glu3
total; Glu2s, singlet at glutamate-2; Glu3s, singlet at glutamate-3; Glu3d, doublet at glutamate-3. PE stands for positional enrichment – this is predicted
mitochondrial enrichment of acetyl-CoA at position C2 and mitochondrial Pyr at position C3 multiplied by factor 10. Curves are fit, and points are experimental data.
(C,D) Experimental data and least-squares fit of time course for labeling of lactate-C3 and fatty acyl methylene (–(CH2 )n –) resonance in proliferating DB-1 melanoma
cells. (C) Time course for labeling of total lactate-C3 (medium + intracellular). (D) De novo lipogenesis in melanoma cells. Time course for labeling of fatty acyl
methylene (–(CH2 )n –) resonance. [This research was originally published in Journal of Biological Chemistry. Shestov et al. (14). © the American Society for
Biochemistry and Molecular Biology.]

for calculating the goodness of fit of these metabolite resonances.
Four types of measurements were used to quantify tumor central
metabolic fluxes: three sets of time courses of (1) glutamate isotopomers (multiplets), (2) total lactate-C3 labeling, (3) acyl groups
of FA resonances determined by NMR in situ, and (4) steadystate 13 C NMR lactate isotopomers. The following time courses
were utilized in the curve-fitting procedure: Glu4Tot (Total: Tot),
Glu4s, Glu4d34, Glu3Tot, Glu3d, Glu2Tot, Glu2s, Lac3Tot, and
acyl methylene (–(CH2 )n –) resonance, yielding a total of nine
curves. Estimation of the model-free parameters was achieved
by fitting labeling patterns of glutamate, lactate, and FAs acyl
methylene groups. Table 1 and the flux map in Figure 1 summarized the fluxes determined by the fitting procedure. Monte Carlo
simulations were used to estimate errors in parameters included
in Table 1.

Frontiers in Oncology | www.frontiersin.org

Model Validation
To validate the bonded cumomer network model, we compared
parameters inferred from the model with experimentally determined values. We measured the O2 consumption rate (MRO2 )
with polarographic oxygen probes during the perfusion experiment. The fluxes obtained by fitting of dynamic 13 C data produced
good agreement between the experimentally observed oxygen
consumption rate, 33 mmol/L-cell/h, and the calculated MRO2 ,
32 mmol/L-cell/h (see Tables 2 and 3). The experimental total
glutamate concentration was 8.6 mM that was in good agreement with the calculated glutamate pool size of 9.2 mM. The
measured glucose consumption rate (MRglc) was 90 mmol/Lcell/h, that compared favorably with the predicted MRglc of
81 mmol/L-cell/h. The measured lactate production flux (CMRlac) was 155 mmol/L-cell/h, whereas the predicted CMRlac was
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TABLE 1 | Extracted fluxes using bonded cumomer modeling.
Reaction

Pentose phosphate pathway (oxidative branch), net PPP
FpppOx

TABLE 2 | Experimental data compared to calculated values determined by
dynamic bonded cumomer modeling (mmol/L-cell/h).

Flux
(mmol/L-cell/h)a

Reaction

Exp. Flux
(mmol/L-cell/h)

Calculated flux
(mmol/L-cell/h)

36
91.0
155.0
5.0
8.6 mM

32
85
150
–a
9.2 mM

3.3 ± 72%

Transaldolase (exchange) relative to glycolysis, TA

44 ± 64%

Oxygen consumption MRO2
Glucose uptake
Pyruvate to lactate
Glutamine uptake
Glutamate concentration

Glucogenic amino acids contribution to pyruvate, Fgaa

5.0 ± 20%

a

TCA cycle rate, Ftca (isocitrate → α-Kg)

10.9 ± 8%

Exchange, Mal-Asp shuttle, Fx (reversible)

11.3 ± 19%

Pyruvate carboxylase Flux, Fpc

0.6 ± 51%

Anaplerotic exchange flux at SucCoA, Fxana

3.0 ± 15%

Net Anaplerotic flux to the TCA cycle, dFana

4.3 ± 15%

Flux of ketogenic AA and FA to Acetyl-CoA formation, Fkaa

0.1 ± 19%

Glutaminolysis Flux, Fgls

0.05 ± 60%

Transketolase 1 (exchange) relative to glycolysis, TK1

21 ± 56%

Transketolase 2 (exchange) relative to glycolysis, TK2

0.5 ± 90%

Pyruvate dehydrogenase Flux, Fpdh

10.8 ± 16%

Citrate synthase flux, Fcs

11.5 ± 14%

Net fumarase activity, Fum→Mal, Ffum

15.3 ± 16%

Fatty acids synthesis, Ffas

0.59 ± 15%

Mitochondrial pyruvate transport, Fmpc

7.1 ± 23%

Malic enzyme (mitochondrion), ME2 + ME3, Fmem

4.3 ± 12%

Malic enzyme (cytosolic), ME1, Fmec

0.6 ± 15%

The flux was not estimated, as glutamine is consumed in numerous reactions we did
not study here. This research was originally published in Journal of Biological Chemistry.
Shestov et al. (14). The American Society for Biochemistry and Molecular Biology.

TABLE 3 | Experimental glucose and glutamine consumption fluxes under
euglycemia (6.4 mM) and hyperglycemic conditions (23.2 mM in medium).

Euglycemia (6.4 mM)
Hyperglycemia (23.2 mM)

Glutamine flux

Glucose flux

0.064
0.035

0.86
0.79

Glutamine [Gln] = 3.0 mM at low glucose and 3.4 mM at high glucose. Fglc, glucose
consumption flux (mmol/109 cells/h) and Fgln, glutamine consumption (mmol/109 cells/h).
Flux ratios were Fglc/Fgln = 22.4 at high glucose and Fglc/Fgln = 13.5 at euglycemia.
This research was originally published in Journal of Biological Chemistry. Shestov et al.
(14). © The American Society for Biochemistry and Molecular Biology.

these data. The excellent agreement between model-predicted and
experimental values validates the model.

Aspartate efflux, dFxasp

0.06 ± 45%

Production Flux of ATP, glycolytic, Warburg, FatpCyt

150 ± 13%

Quantifying ATP Production Routes

Production Flux of ATP, mitochondrial, oxphos, FatpOx

154 ± 12%

The predicted fluxes were used to calculate contributions of glycolysis and oxidative phosphorylation (oxphos) to ATP production. We assumed that the oxidative phosphorylation P/O ratio
equals 1.5 for FADH2 and 2.5 for NADH oxidation. To assess the
contribution of glucose, FAs and glucogenic AAs and glutamine
to generating reducing power, we calculated the fluxes for each of
these metabolites. For each of the above substrates, we calculated
the NADH/FADH2 reaction flux based on the different labeling
patterns that we were able to track both from the labeled and
unlabeled C atoms. The combined cytosolic ATP production flux
was 150 mmol/L-cell/h, and the mitochondrial compartment produced 154 mmol/L-cell/h due to oxidative phosphorylation. The
results are presented in Table 1.
Consequently, about 50% of the energy of this tumor model
comes from oxidative metabolism, whereas many authors have
suggested that tumors derive most of their energy from aerobic
glycolysis. The glycolytic contribution will, no doubt, increase
in vivo where tumors are often located in regions of hypoxia,
which produce a Pasteur effect, and, hence, a shift toward
glycolytic metabolism; however, it is likely that many tumors like
melanomas will be strongly dependent on oxidative metabolism
for their energy source, particularly in tumors that express the
V600E BRAF mutation, about 50% of human melanomas. (68)
High fluxes of pyruvate mitochondrial transport (~70% of the
TCA cycle activity) and mitochondrial ATP production are
promoted by melanoma associated BRAF mutation. Recent work
(69) has demonstrated that BRAF V600E mutated melanoma
cells exhibit increased pyruvate entry through the activated
PDH. PDH flux (~106% of the TCA flux) is regulated by

Warburg parameter (net LDH/MPC flux ratio)
Combined glycolysis and PPP flux from G6P to pyruvate
Glutamine consumption flux (for protein, nucleotides, amino
acids, glutathione, etc)

21 ± 24% (unitless)
152.1 ± 12%
4.9 ± 10%b

Net LDH activity, Pyr → Lac, Fldh

150 ± 12%

Lactate transport, Vmaxlac

395 ± 12%

Lactate transport, Michaelis–Menten parameter, Km

3.5 mM ± 70%

a

Calculated rates of flux are expressed in millimoles per liter-cell per hour with relative SDs
in percent for pathways shown in Figure 1. Warburg parameter is the ratio of the net flux
through lactate dehydrogenase (LDH) to the mitochondrial pyruvate carrier influx (MPC).
b
SD was estimated based on experimental measurements of glutamine consumption.
This research was originally published in Journal of Biological Chemistry. Shestov et al.
(14). © the American Society for Biochemistry and Molecular Biology.

150 mmol/L-cell/h. We note that we did not use experimentally measured fluxes as constraints in our Bonded Cumomer
metabolic flux analysis.
Tables 2 and 3 also compare glucose and glutamine uptake
under euglycemic (6 mM glucose) and hyperglycemic (23 mM)
conditions. Under euglycemic conditions, glutamine influx
approximately doubles, whereas glucose consumption remains
essentially unchanged.
Finally, we were able to generate a flux map that was included
with the bionetwork in Figure 1. This figure shows the extracted
metabolic fluxes with the predicted oxygen consumption rate
MRO2 . Numbers indicate fluxes in mmol/L-cell/h. See Table 1
for definitions and values of the derived fluxes; Table 2 summarizes the predicted and calculated metabolic rates derived from
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phosphorylation/dephosphorylation mediated by PDH kinase
(PDK) and PDH phosphatase (PDP). The oncogene BRAF V600E
causes concerted activation of PDH complex by downregulation
of PDK1 expression and upregulation of PDP2 thereby promoting
oxidative pyruvate utilization and leading to increased cellular
respiration.

Pentose Phosphate Pathway

We used the Bonded Cumomer flux model to fit 13 C NMR steadystate data acquired after 8 h incubation of DB-1 cells with [1,213
C2 ]glucose tracer. The fitted steady-state data were Lac3Tot,
Lac2Tot, Lac3s, Lac3d23, Lac2s, and Lac2d23 multiplets. All the
experimental 13 C NMR spectra and the results of fitting are shown
in the Figure 5. The extracted fluxes relative to glycolytic flux are
presented in Table 1. Flux SDs were calculated by Monte Carlo
calculations. Flux through the oxidative PPP was estimated to
be 3.6% of the glycolytic rate. Given the extensive experimental
data that have been obtained for the lactate 13 C NMR multiplets,
we were also able to estimate non-oxidative exchange fluxes (the
smallest rate for reversible reaction) of the classical PPP (Figure 1),
which are presented in Table 1. Transketolase 1 and transaldolase
exchange fluxes in the non-Ox PPP branch were consequently
relatively high at 21 and 44%, respectively, and transketolase 2
activity was close to 0. The flux SDs (Table 1) demonstrate that all
fluxes through PPP were resolved with relatively poor resolution
when using only 13 C NMR isotopomers of lactate as a reporter
molecule. NADPH production flux via the oxidative PPP pathway
was estimated to be 6.6 mmol/L-cell/h.

FIGURE 5 | High-resolution 13 C and 1 H NMR spectra of lactate from
DB-1 cells incubated with [1,2-13 C2 ] glucose and experimental lactate
multiplets vs. fit. (A) 13 C NMR spectra. The left panel shows the NMR
spectrum at the chemical shifts around lactate C2, and the right panel shows
the spectrum around lactate C3. 2s, lactate singlet at C2 position; 2d32,
lactate C2 doublet with carbon coupling between the carbon 2 and 3
positions; 3s, lactate singlet from the C3 position; 3d23, lactate C3 doublet
with carbon coupling between the carbon 2 and 3 positions. (B) Protonobserved carbon-edited (POCE) 1 H NMR spectra. The upper panel shows the
labeled lactate and the lower panel shows the unlabeled lactate. (C)
Experimental multiplet fraction (left bars, black) vs. fitting (right bars, patterned)
for lactate C3 and C2, and the predicted lactate C1 multiplets, based on the
evaluated oxidative and non-oxidative branches of the PPP. Error bars
indicate SDs. The extracted oxidative PPP flux and the relative exchange
fluxes for transketolases and aldolase are presented in Table 1. [This research
was originally published in Journal of Biological Chemistry. Shestov et al. (14).
© the American Society for Biochemistry and Molecular Biology.]

Quantifying Glutaminolysis Flux
Our recent focus has turned to refinement of the details of glutaminolysis because of its critical role in the metabolism of many
malignancies. For example, one glutamine molecule could produce up to 22.5 ATP molecules. Therefore, even a small amount
of glutaminolysis can have a major effect on the bioenergetics of
cancer cells. In DB-1 melanoma under hyperglycemic conditions,
glutamine uptake flux ranged up to 50% of the TCA cycle flux.
Under euglycemic conditions, glutamine uptake doubled reaching
approximately the same level as TCA cycle flux. Glutamine uptake
can lead to protein synthesis, glutathione synthesis, or nucleotide
synthesis as well as to ATP production by the glutaminolysis
pathway (see below) or to cytosolic reductive carboxylation (RC)
driven by glutaminase 1 (GLS; it is considered to be present
both in mitochondria and cytosol) or other glutamine–glutamate
conversion enzymes in cytosol and isocitrate dehydrogenase 1
(IDH1) (70). It was, therefore, important to refine the metabolic
analysis of DB-1 melanoma to accurately assess the contributions
of the glutaminolysis pathway in these tumor cells (See Figure 1).
In order to quantify the glutaminolysis contribution to energy
production, we modified the bionetwork simultaneously allowing
net glutamine influx into mitochondria through glutaminase 1
and 2 (GLS and GLS2) (Figure 1).
“Classical” glutaminolysis includes uptake of glutamine by
the cell, transport to mitochondria, conversion to glutamate
through mitochondrial glutaminase 1 or 2 (GLS and GLS2), and
finally entry into the TCA cycle to α-ketoglutarate via GLUD1
and GLUD2 or via mitochondrial aminotransferases (GPT2 and

Frontiers in Oncology | www.frontiersin.org

GOT2). Alternatively, glutaminolysis could partially occur in the
cytosol by producing glutamate or α-ketoglutarate from glutamine and eventually by entry of those metabolites in to the
TCA cycle via α-ketoglutarate. Further flux in the TCA cycle then
moves to malate where malate–pyruvate cycling occurs (Figure 1).
There are two pathways for pyruvate-malate cycling. One pathway
involves conversion of malate via mitochondrial malic enzyme
(ME2) to pyruvate; it then returns to oxaloacetate via PC, or it
can go from pyruvate to acetyl-CoA leading to citrate. The second
pyruvate cycling pathway goes from malate in the mitochondria
through a transporter into the cytosol and from there to cytosolic
pyruvate via cytosolic malic enzyme (ME1). The cytosolic pyruvate can return to the mitochondria through the MPC or it can
be converted to lactate via LDH or to alanine via alanine aminotransferase (GPT1). The BC approach can distinguish between
these pyruvate–malate pathways or their combinations under real
conditions (Figure 1).
We continue the analysis of data of DB-1 melanoma cells treated
with [1,6-13 C2 ]glucose as the tracer with respect to sensitivities of the experimental multiplets to glutaminolysis. Dynamic
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isotopomer control analysis (ICA) indicates that the curves resulting from fitting of the C4-labeled glutamate multiplets, particularly the glutamate 3,4 doublet-glu4d34 resulting from simultaneous labeling of C3 and C4 (during the second TCA cycle turn)
and the singlet resulting from glutamate labeling exclusively at
C4 (during the first turn of the TCA cycle) are very sensitive to
flux through the glutaminolysis pathway even when only natural
abundance medium glutamine has been used. See for example
Figure 2A, where we display the dynamic multiplet control coefficients with respect to glutaminolysis activity for the glutamate
C4 total and the glutamate C4 singlet and 3,4 doublet-4d34, and
for the glutamate C3 and C3d doublet and glutamate-C2 and C2s
singlet. This figure clearly indicates that glutamate labeling kinetics is sufficiently sensitive to glutaminolysis flux and that there
is no need to purchase or synthesize exotically labeled glutamine
(with 13 C, 15 N, or 2 H labeling) to evaluate glutaminolysis. Control
simulation was based on the optimal set of extracted fluxes, and
glutaminolysis flux was set at 5% of the TCA cycle flux. The plotted
dynamic glutamate multiplet control coefficients indicate that the
glutamate doublet 4d34 is the most sensitive glutamate multiplet
with respect to glutaminolysis net flux during the first ~1.5 h
when the sensitivity of the RGlu4d34 doublet is positive (positive
mode) and afterwards when the RGlu4s singlet 4s becomes most
sensitive in the negative operation mode. The data in the right
panel of Figure 2A demonstrate the superiority of the sensitivity to
glutaminolysis flux of the glutamate 3d doubled at the beginning
and glutamate 2s singlet during the time course after ~1.5 h.
We then evaluated the contribution of glutaminolysis flux to
overall energy production of DB-1 melanoma cells. We found
that for this tumor line, glutaminolysis flux through the truncated
TCA cycle and via pyruvate–malate cycling by malic enzyme
ME2 is essentially 0. This conclusion resulted directly from the
ability of the model to detect glutaminolysis flux by fitting of data
on the glutamate multiplets (see above). To further confirm this
conclusion, we forced the model to accommodate glutaminolysis
flux between 5 and 20% of the TCA cycle flux. Invariably, this
grossly deteriorated the goodness-of-fit of the isotope kinetic data
to the model (results not shown).
Even though glutaminolysis does not contribute substantially
to mitochondrial ATP production, there is still substantial mitochondrial malic enzyme flux (combined activities of NADH producing ME2 and NADPH producing ME3), which is equal to
approximately 40% of the TCA flux (see Table 1).
There has been considerable interest in glutamine metabolism
as a key source of tumor energy production linked to c-myc
expression (71–75). Our model of tumor metabolism (Figure 1)
contains a specific glutamine transporter on the cell membrane.
The classical model of glutaminolysis includes an additional
specific glutamine transporter on the mitochondrial membrane
that leads to mitochondrial glutaminase (GLS2 or GLS), which
converts glutamine to glutamate, which is then converted to αketoglutarate by enzymes, such as GLUD1 and GLUD2. Two
additional transaminases can carry out the glutamate to αketoglutarate exchange, aspartate aminotransferase, and alanine
aminotransferase. The α-ketoglutarate then produces reducing
equivalents via the oxidative branch of the TCA cycle leading
to ATP production by oxidative phosphorylation. Various pathways, including the malate-aspartate shuttle, PC, malic enzyme,
Frontiers in Oncology | www.frontiersin.org

and phosphoenolpyruvate carboxykinase (PEPCK1 and 2) all
contribute to metabolism of the glutamine carbon atoms. As
previously noted, glutamine metabolism can lead to production
of 22.5 molecules of ATP per glutamine molecule. In the case of
DB-1 melanoma cells under hyperglycemic conditions, glutamine
influx constituted about 50% of the TCA cycle flux, with about
double this level of glutamine uptake under euglycemic conditions (Tables 2 and 3). However, the transaminase reactions are
reversible and may exhibit high exchange fluxes in both directions
with very little net glutamine uptake by the TCA cycle and nearly
no energy production from the glutaminolysis pathway in DB-1
cells. It is important to note that because carbon atoms of glutamate originating from glucose will be isotopically labeled (first on
C4 position and then on C2 and C3, etc.), whereas carbons coming
from glutamine will be unlabeled, it was possible to distinguish the
two pools of carbon atoms originating from these two substrates.
The data fitting clearly indicated that the net flux from glutamine
being metabolized via the TCA cycle was very small.
We also conducted a sensitivity analysis to show that using
[1,6-13 C2 ] glucose tracer alone is enough to reliably calculate glutaminolysis flux in malignant cells and tissues. Figure 2A shows
that the glutamate-C4 doublets due to C3–C4 coupling (glu4d34)
is most sensitive to glutaminolysis and all experimental glutamate
multiplets, including total positional enrichments at glutamate
C4, C3, and C2 are sensitive to the net flux of unlabeled glutamine
entering the TCA cycle. Fitting analysis indicated that there was
little net influx from glutamine into the TCA cycle. Note also that
this conclusion can also be reached from 13 C NMR data without
the use of labeled glutamine.
By contrast, some investigators utilizing mass spectrometry
have equated glutamine uptake minus glutamate release with net
glutaminolysis flux (76). In the present case, the net influx of
glutamine is ~5 mmol/L-cell/h, which, if it were equated with
glutaminolysis flux, would have been interpreted as 113 mmol/Lcell/h of ATP per h or about 75% of the glycolytic production of ATP. Under euglycemic conditions, which produce about
twice the level of glutamine uptake, such an analysis would have
attributed about 50% higher ATP production to glutaminolysis
rather than to glycolysis, and most of the tumor energy production
would have been attributed to glutaminolysis. This is incorrect
in our case; in reality the net glutaminolysis flux under hyperglycemic conditions is ~0.1 mmol/L-cell/h or ~2 mmol ATP/Lcell/h or ~1% of the glycolytic ATP production rate. Bonded
Cumomer analysis provides a method for making this crucial
distinction. Our labeled LC-MS data for the TCA cycle intermediates with [U-13 C5 , U-15 N2 ] glutamine confirmed that no
glutaminolysis occurred under euglycemic conditions vs. hyperglycemia (Figure 6). The absence of change in glutaminolysis
or RC flux is evident from similar mass-isotopomer distribution
(MID) of several key metabolites. Our finding of nearly zero glutaminolysis flux contradicts the view of Scott et al. (77), who, on
the basis of glutamine uptake and label appearance in some TCA
cycle metabolites, concluded that glutamine was utilized as an
anaplerotic substrate of several human melanoma lines. However,
these authors failed to conduct a rigorous metabolic modeling
analysis to measure flux through the TCA cycle. Consequently,
they were unable to distinguish between actual flux through
the cycle via glutaminolysis and exchange labeling between
13
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(see Figures 3 and 4D). FA synthesis occurs first by cytosolic
citrate production from glucose and through RC in cytosol from
glutamine through isocitrate dehydrogenase (IDH1 isoform). By
ATP citrate lyase, cytosolic citrate is converted to oxaloacetate
and cytosolic acetyl-CoA, which is converted further to malonylCoA by the rate-limiting acetyl-CoA carboxylase beta (ACC-beta)
and through FAs synthases to elongated precursors via sequential
addition of acetyl-CoA, eventually leading to palmitate production. Palmitate is further elongated or desaturated to produce
numerous other FAs. To address de novo FA flux production, we
utilized the BC model with cytosolic FAs and their precursors as
well as membrane FAs as the second FA pool. We calculated FA
concentrations based on the total FA content of approximately
20% of cell dry weight of 200 mg/109 cells (5 × 108 cells = 1 ml).
Total FA content referenced to palmitate is at the level of several
tens of mmol/L-cell. We iteratively varied the ratio of cytosolic to
membrane FA and found the best fit at approximately 10 times
more FA in the cytosolic membrane compartment (Figure 4D).
The de novo flux of conversion of glucose to FA was 0.59 mmol/Lcell/h and NADPH consumption flux in FA biosynthesis was
8.4 mmol/L-cell/h.
While glutamine-derived carbons have been unlabeled, we have
monitored lipogenesis by 13 C NMR detecting methylene carbon
acyl groups originating from labeled glucose (Figures 3A and
4D). Table 1 indicates that de novo lipogenesis corresponds to
~6% of the TCA cycle flux under hyperglycemic conditions.
However, this does not include possible direct contributions
from unlabeled glutamine (i.e., through cytosolic RC by isocitrate dehydrogenase IDH1 or mitochondrial IDH2) and potentially from cytosolic acetyl-CoA synthetase 2 (ACSS2) reaction,
which involve participation of cytosolic acetate or acetate from the
medium (78).
This modest flux for de novo FA synthesis requires a large contribution of NADPH cofactor production (~8.3 mmol/L-cell/h).
NADPH could be produced by the oxidative branch of the
PPP, ME, or IDH activities or by serine–glycine one-carbon
metabolism (folate metabolism). Our calculated malic enzyme
activities in mitochondria (even if all this activity is represented by
ME3) would account for 4.3 mmol/L-cell/h and cytosolic NADPH
flux (ME1, 0.6 mmol/L-cell/h) would not account for the required
high level of NADPH flux. A recent elegant study (79) suggested
that in some cancers folate metabolism is the biggest producer
of NADPH. Based on these data (48), we estimated that the
serine–glycine one-carbon SGOC pathway cannot account for the
required NADPH consumption. In light of our 13 C NMR lactate
labeling data, the oxidative branch of the PPP is the main producer of NADPH in these cancer cells (6.6 mmol/L-cell/h). This
constitutes ~80% in agreement with the NADPH consumption
rate during FAs biosynthesis. Thus, the flux through the oxidative
PPP appears to be ~80% sufficient to supply all of the NADPH
required for FA production and is the main supplier of reducing
equivalents in DB-1 melanoma. A 20% difference in the rates of
NADPH production and consumption indicates that alternative
sources of NADP reduction, considered above, need to be taken
into account. We also found that mitochondrial-pyruvate–malate
cycling was very high (4.3 mmol/L-cell/h). This could also contribute to defense against reactive oxygen species by producing
sufficient NADPH via ME3.

FIGURE 6 | Mass-isotopomer distribution (MID) for the TCA cycle
intermediate and acetyl-CoA measured at hyperglycemic and
euglycemic conditions during [U-13 C5 ] glutamine labeling. MID of (A)
citrate, (B) malate, (C) succinate, and (D) acetyl-CoA. The figure clearly
demonstrates that there are no significant differences in labeling patterns of
key metabolites (p-value was always >0.05) between 5 mM glucose and
25 mM medium glucose conditions. [This research was originally published in
Journal of Biological Chemistry. Shestov et al. (14). © the American Society
for Biochemistry and Molecular Biology.]

α-ketoglutarate and glutamate without any net flux. In addition,
glutamine could be used for many other metabolic processes
besides energy production, e.g., protein and nucleotide synthesis.
If the net uptake of glutamine is 5 mmol/L-cell/h with negligible
contribution to energy production, glutamine must be contributing primarily to anabolic processes, such as AA, nucleotide, and
protein production as well as to de novo lipogenesis.

Effect of Hyperglycemia/Euglycemia on
Glutamine and Fatty Acid Metabolism

The MID of several TCA cycle metabolites from [U-13 C5 , 15 N2 ]
glutamine labeling experiments is shown in Figure 6 at different
glucose concentrations in the medium – at 5 mM for euglycemia
and 25 mM for hyperglycemia. With this tracer, increased glutaminolysis flux resulted in increased abundance of M + 4 massisotopomer of citrate, succinate, and malate (70), whereas RC
resulted in increased M + 3 for malate, M + 4 for succinate, and
M + 5 for citrate. RC and increased glucose contribution to the
FAs production also disturbs the acetyl-CoA mass-MID. Figure 6
clearly shows that there are no significant differences in labeling
patterns of all four metabolites. Consequently, based on bioreactor
data, we can exclude any major change in glutaminolysis flux as
well for FA production during hyperglycemia vs. euglycemia.

Quantifying De Novo Lipogenesis
Flux in DB-1 Cells

During culturing of DB-1 cells with [1,6-13 C2 ] glucose, progressive labeling of FAs was observed for multiple resonances
Frontiers in Oncology | www.frontiersin.org
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cell lines (p = 0.002 and 0.03 for DLCL2 and Ramos, respectively; n = 3) with increased differences at 24 and 48 h. Changes
of lactate and glucose concentrations in the medium indicated
diminished glycolysis following rapamycin treatment with corresponding changes in lactate secretion and glucose uptake per
cell. Lactate secretion and glucose uptake exhibited maximum
differences between vehicle- and rapamycin-treated cell cultures
at 24 h in contrast to intracellular lactate that remained approximately unchanged. The amount of secreted lactate per cell was
three to four orders of magnitude greater than the intracellular
lactate levels, which indicates that most of the lactate generated by
cellular metabolism was secreted by the cell. Nonetheless, the level
of intracellular lactate was more sensitive than secreted lactate
levels for distinguishing metabolic differences between vehicleand rapamycin-treated cells. This was, in part, due to the intracellular lactate concentration remaining essentially constant after
rapamycin treatment.

Lymphoma Studies
Rapamycin Inhibits mTORC1 Signaling and Lowers
Lactate Concentration in B-Cell Lymphoma Cells
The effects of rapamycin on mTORC1 signaling and cell
growth were first examined in four B-cell lymphoma cell lines,
sub-classified either as germinal-center type DLBCL (DLCL2,
Val, and Ly18) or Burkitt (Ramos). As indicated by loss
of mTORC1-dependent S6rp phosphorylation, rapamycin suppressed mTORC1 activity in all the cell lines and profoundly
inhibited BrdU uptake-detected cell proliferation (15).
We have evaluated the effect of rapamycin on the cellular concentration of lactate in NHL cells by 1 H MRS (Figures 7A,B)
because mTOR has been implicated in various aspects of cell
metabolism. To varying extents rapamycin significantly decreased
intracellular lactate relative to controls in all four cell lines (15).
Significantly, the relative reduction in intracellular lactate concentrations in rapamycin treated cells vs. controls was more pronounced after 48 than 24 h exposure to rapamycin and correlated
with the suppression of cell growth indicating that the effect is
not directly due to drug–enzyme interaction or direct effects on
mTOR signaling but is most likely due to gene translation.

Rapamycin Inhibits Expression of Hexokinase II
While inhibition of mTORC1 signaling by rapamycin reaches an
optimum within minutes after drug administration (80–82), the
drug’s effects on the lactate concentration were not detectable until
8 h post-treatment and became more pronounced at 24 and 48 h
in cultured cells (15). This marked timing difference indicates
that the inhibition of glycolysis does not directly result from
inhibition of the mTORC1 signaling but most likely originates
from diminished expression of enzymes involved in the glycolytic
pathway. To test this assumption, we performed gene expression profiling of the DLCL2 and Ramos cell lines treated with
rapamycin or medium alone (Figure 7C). The component of the

Kinetics of the Rapamycin-Induced Suppression
of Lactate Concentration
To determine how early the rapamycin-induced metabolic
changes can be detected, we examined the intracellular lactate
concentration at 2, 4, 8, 24, and 48 h in two B-cell lymphoma
cell lines (15). While 2 and 4 h exposure to rapamycin did not
have a definitive effect, we noted statistically significant differences between vehicle- and rapamycin-treated cells at 8 h in both

FIGURE 7 | Rapamycin-induced mTOR inhibition and changes in intracellular lactate levels and glycolytic gene expression profiles. (A) 1H MRS
spectra of DLCL2 cells at 24 h (control vs. rapamycin-treated); lactate (1.3 ppm) and the reference TSP peaks (0 ppm, indicated as STD). (B) Intracellular lactate
concentration (mole/cell) for the four listed B-cell lymphoma cell lines treated with 200 nM rapamycin or medium alone for 24 and 48 h (n = 3 for each condition). (C)
Expression of the glycolysis-related genes in the depicted cell lines treated for 6 h with rapamycin or medium alone. (D) Kinetics of the rapamycin-induced changes in
hexokinase II protein expression. Inhibition of S6rp phosphorylation, an indicator of mTOR signaling, is also shown. [This research was originally published in NMR in
Biomedicine. Lee et al. (15). © John Wiley & Sons Inc.]
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glycolytic pathway whose gene expression was most profoundly
inhibited by the rapamycin treatment was hexokinase II although
some other glycolytic genes showed similar trends. The steady loss
of hexokinase II expression was confirmed on the protein level in
all the cell lines examined (Figure 7D).

cell cycle-associated marker mib1 (15). Western blots confirmed
effective and specific mTORC1 inhibition, which revealed greatly
diminished S6rp phosphorylation and intact phosphorylation
of Akt. Prolonged treatment with rapamycin resulted in tumor
growth arrest for the DLCL2 cell line and a marked decrease in
tumor volume for the Ramos cell line (Figure 8). It is noteworthy
that these effects were preceded by decreases in tumor lactate concentrations measured by in vivo MRS. The decrease was already
statistically significant at 48 h following initiation of rapamycin
treatment and increased at 96 h. At 2 days after initiation of treatment, the effect of rapamycin on tumor volume was not yet noticeable while tumor lactate had already significantly decreased. These
observations strongly suggest that in vivo measurement of lactate
originating from the tumor provides an early marker predictive of
effective mTOR inhibition that correlates with substantially later
tumor shrinkage.

Rapamycin-Induced Suppression of Lactate
Concentration Directly Correlates with Inhibition of
Lymphoma Growth In vivo
To determine if the rapamycin-induced suppression of lactate concentration can also be detected in vivo, we evaluated xenotransplanted lymphoma models (Figure 8), the DLCL2 and Ramos
B-cell lines studied in greatest detail in vitro as described above.
The tumors displayed the appropriate transformed lymphoid cell
morphology and human B-cell phenotype confirming that they
originated from the implanted lymphoma cell lines.
Administration of rapamycin to mice with DLCL2 and Ramos
xenografts inhibited mTORC1 signaling and decreased the proliferative rate of the lymphoma cells as determined by suppression of S6rp phosphorylation and decreased expression of the

Discussion of Rapamycin Data
The above results clearly document that mTOR inhibition can be
monitored in vitro and in vivo by measuring changes in lactate

FIGURE 8 | Rapamycin-induced inhibition of tumor growth and glucose metabolism in vivo. Xenotransplants of DLCL2 cells (left panel) and Ramos cells
(right panel). (A) Tumor growth curve. The data are presented as mean ± SD (n ≥ 5 in each group). (B) Time course in vivo localized MRS. (C) Lac/H2 O ratios
normalized to the pretreatment values; mean ± SE (n = 5). Statistically significant changes in Lac/H2 O were observed at 48 h and after from initiation of rapamycin
treatment in both xenografts while control tumors (n = 5) did not have significant changes in Lac/H2 O until 96 h. [This research was originally published in NMR in
Biomedicine. Lee et al. (15). © John Wiley & Sons Inc.]
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concentration. Accumulating evidence indicates that mTORC1
can be activated by a variety of cell–surface receptor complexes.
While the original studies implicated the activation of receptors for the insulin-family growth factors (83–85), subsequent
observations by the Wasik laboratory (80–82) and by others (86–
91) demonstrated that a large spectrum of receptors and their
ligands triggered mTORC1 activation. These include interleukin2, anaplastic lymphoma kinase, CD40 ligand, notch, thyroidstimulating hormone, fibroblast growth factor-9, polycystein-1,
and prostaglandin F2a. These diverse ligand–receptor complexes
activate mTORC1 through the signaling pathways PI3K/Akt (92–
94), MEK/ERK (95), and possibly Syk (96). Therefore, the inhibition of these pathways should also be amenable to detection
by monitoring changes in glycolysis. Given that these pathways
are frequently deregulated in malignant cells and clinical-grade
inhibitors are already available, evaluation of glucose metabolism
as a surrogate for monitoring mTOR activity may prove useful
in the management of cancer patients treated with a variety of
kinase inhibitors. Indeed, inhibition of the oncogenic BCR/ABL
tyrosine kinase led to decreased glucose uptake and lactate production (97, 98), all but certainly indicating that mTORC1 signaling was involved (99). Hence, the apparent lack of specificity of
lactate actually reflects its versatility. Provided that a single kinase
inhibitor is administered, there is no lack in specificity of detecting
response to the drug; if multiple kinase inhibitors are used, then
lactate still serves as a biomarker for the combination.

not only glucose metabolism but also TCA cycle activity, de
novo FA and sterol biosynthesis, pyruvate cycling activity, and
flux through pentose phosphate pathway. Glutaminolysis should
also be affected due to novel PPAT gene expression, which is
responsible for enzymatic glutamate production from glutamine
(see footnote “b” in Table 4).

Cell Perfusion and 13 C NMR Spectroscopy
Figure 9A shows data obtained from DLCL2 cells immobilized
in agarose beads and perfused with normoxic (20% O2 , 75% N2 ,
5% CO2 ) media containing 5 mM [1,6-13 C2 ] glucose over a 12-h
period in a 10 mm diameter NMR bioreactor. Cells were studied
before treatment and 24 and 48 h (not shown) after treatment with
rapamycin. Using a two-compartmental enzyme kinetic model,
we calculated lactate production rates. The results were 6.9 mM/h
(pretreatment) and 1.6 mM/h (post-treatment), which indicate a
profound decrease in glycolysis. There is also a decrease in labeling
of Glu C4 reflecting a decrease in TCA cycle flux. Alanine and
fatty acid labeling are also diminished, and glycogen stores have
been completely depleted, probably as a result of decreased energy
production by both glycolytic and TCA cycle pathways.
In vivo 13 C NMR Studies of DLCL2 Cell Metabolism
Figure 9B shows the time course of 13 C MR spectra measured
after infusion of [1,6-13 C2 ] glucose into a mouse with a 12 mm
DLCL2 xenograft (500 mm3 ) growing on its flank. The inset to
this figure shows the MR image of the tumor and the Hadamard
voxel that localizes the spectral data in the tumor (i.e., insuring no
contributions from external tissues). These studies demonstrate
the feasibility of performing 13 C MRS studies non-invasively in
these in vivo lymphoma tumor models in mice. The spectra show
the time course of labeling of tumor metabolites by transfer of
13
C by metabolism of the labeled glucose over 120 min with each
spectrum measured in 15 min. The same animal was studied
before and 4 days later after seven doses of rapamycin (10 mg/kg)
with two doses administered per day (bottom of Figure 9B).

Genomic Analysis of mTOR Inhibition
In view of a recent report (100) that several metabolic pathways
were modified in mouse fibroblasts with hyper-activated mTOR,
we analyzed changes in expression of metabolic genes in DLCL2
and Ramos cells induced by rapamycin. Table 4 lists significantly
affected (up- and downregulated; p < 0.02, n = 3) of representative metabolic genes in DLCL2 cells (Ramos data are similar).
The anticipated related alterations in the cellular metabolism
indicate that in the DLCL2 cells mTOR inhibition diminishes

TABLE 4 | Changes in gene expression following treatment of DLCL2 cells with rapamycin.a
Entrez ID
Upregulated
5106
Downregulated
3099
57546
3419
5471
31
2180
23171
22934
1717
6307
1723
5198

Gene Symbol

Enzyme name

EC number

PCK2

Phosphoenolpyruvate carboxykinase 2 (mit)

EC 4.1.1.32

HK2
PDP2
IDH3A
PPAT
ACACA
ACSL1
GPD1L
RPIA
DHCR7
MSMO1
DHODH
PFAS

Hexokinase 2
Pyruvate DH phosphatase subunit 2
Isocitrate DH 3 (NAD +) alpha (mito)
Amidophosphoribosyl transferase
Acetyl-CoA carboxylase alpha
Acyl-CoA synthetase long-chain member 1
Glycerol-3-phosphate dehydrogenase 1-like
Ribose 5-phosphate isomerase A
7-dehydrocholesterol reductase
Methylsterol monooxygenase 1
Dihydroorotate dehydrogenase
Phosphoribosylformylglycinamidine synthase

EC 2.7.1.1
EC3.1.3.43
EC1.1.1.41
EC2.4.2.14
EC6.3.4.14
EC 6.2.1.3
EC 1.1.1.8
EC 5.3.1.6
EC1.3.1.21
EC1.14.13.72
EC 1.3.5.2
EC 6.3.5.3

Fold change

P value

Pathway Affected

1.51

0.000434

Pyruvate cycling

−1.78
−1.54
−1.60
−1.73
−1.80
−1.52
−1.56
−1.58
−1.72
−1.74
−1.51
−1.51

0.00515
0.0150
0.000673
0.0163
0.00518
0.0161
0.00446
0.00451
0.00363
0.0165
0.000190
0.00120

Glycolysis
PDH, TCA
TCA Cycle
Glutaminolysisb
Fatty acids
Fatty acids
Glycerophospholipid
Pentose phosphate
Cholesterol
Cholesterol
Pyrimidine metabolism
Purine metabolism

a

Data were compiled from KEGG database. Gene expression of a large number of enzymes demonstrated statistically significant changes, but only one or two representative enzymes
are listed for pathways showing changes greater than 50%.
b
This is a new link for glutamine to glutamate interconversion through operation of enzyme 5-phospho-β-D-ribosylamine:diphosphate phospho-α-D-ribosyl-transferase (glutamateamidation reaction).
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FIGURE 9 | Time course 13 C NMR spectra of perfused DLCL2 lymphoma cells and in vivo tumors upon rapamycin treatment. (A) Perfused DLCL2 cells
in 9.4T/8.9 cm vertical bore Varian NMR spectrometer. 4 × 108 cells were encapsulated in agarose and perfused in a 10 mm diameter NMR perfusion chamber with
RPMI 1640 medium containing 5 mM [1,6-13 C2 ] glucose maintained under an atmosphere of 20% O2 , 75% N2 , 5% CO2 at 37°C. (B) In vivo 13 C MRS spectra of a
nude mouse with 12 mm DLCL2 tumor implanted in its flank. Spectra were measured before and after rapamycin treatment with seven consecutive doses (10 mg/kg)
administered by oral gavage twice daily. During the study, 450 mM [1,6-13 C2 ] glucose was infused through the tail vein at variable infusion rates. Each spectrum was
acquired in 15 min on a 9.4 T/31 cm spectrometer with a home-built 13 mm loop-gap resonator.

The rate of lactate labeling has decreased, whereas the rate of
alanine labeling appears to have increased. Glutamate-C4 was
detectable and appears to have decreased after rapamycin treatment, suggesting a decrease in TCA cycle flux. The glycogen peak
appears very small in both sets of spectra and seems to have been
diminished but not eliminated after treatment. These are among
the first in vivo spectra we or anyone else we are aware of have
reported. We are pursuing a number of strategies for improving
the resolution and S/N ratio. Obviously, higher magnetic fields
or cryoprobes would increase the sensitivity, but even with the
equipment at hand it is clearly feasible to obtain quantitative data
in vivo.
A computational analysis (Figure 10) of the time course
in vivo data from a mouse to a two-compartment non-steadystate enzyme kinetic model generated total lactate production
and clearance rates (indicated in the figure caption). The model
included glycolysis, alanine production, and exchange of cytosolic
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and vascular/interstitial lactate through MCT1 (the dominant
monocarboxylic acid transporter). The calculated fluxes indicate
a decrease in glycolytic metabolism caused by treatment with
rapamycin. Clearly a more comprehensive analysis, including
other metabolic pathways that contribute to lactate production
is required, but this demonstrates feasibility of our precise data
analysis approach.

LC-MS Studies of DLCL2 Tumor Cells
Preliminary studies of DLCL2 cells in suspension culture have
been initiated in Dr. Blair’s laboratory (Figure 11). Cells were
grown in batch culture. Harvested cells were spiked with [U-13 C]
lactate, citrate, and succinate as internal standards. The extracted
metabolites were separated by a reverse-phase ion-paring chromatography and analyzed by MS. Note that these are steady-state
measurements, which only provide information about relative
fluxes. Kinetic data are required for absolute flux measurements.
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TABLE 5 | Pathway activities for DLCL2 cells based on 13 C LC-MS data.a
Pathway name
Reductive carboxylation (cytosolic)
Glutaminolysis
Mitochondrial pyruvate carrier
Pyruvate dehydrogenase complex
Pyruvate carboxylase (mitochondrial)
De Novo fatty acid production

Control

Rapamycin

P-value

0.29 ± 0.05
0.27 ± 0.10
0.63 ± 0.06
0.60 ± 0.07
0.075 ± 0.030
0.39 ± 0.07

0.17 ± 0.03
0.014 ± 0.02
0.90 ± 0.09
0.56 ± 0.05
0.39 ± 0.09
0.23 ± 0.05

0.0235
0.0122
0.0124
0.466
0.0045
0.0322

Presented as real parameter value ± error in terms of standard deviation (SD). Errors are
based on Monte Carlo simulations assuming Gaussian noise with 0 mean and σ = 0.01
for SD; synthetic renormalized steady-state mass-isotopomers fit by fragmented cumomer
model using Simplex.
a

state was achieved. A preliminary analysis fitted the LC-MS isotopomer data (aspartate, glutamate, lactate, malate, succinate,
citrate, and α-ketoglutarate, Mo, M1, . . ., Mn , n = number of carbons) to all the metabolic pathways included in the fragmented
cumomer model (Shestov et al., manuscript in preparation) (13,
48, 49). There was excellent agreement between observed and
calculated isotopomer levels (data not shown). The metabolic network includes all the pathways included in the bonded cumomer
model (Figure 1). Table 5 summarizes changes in flux through
various pathways for which there was adequate significance.
Rapamycin produced dramatic changes in RC (41% decrease),
glutaminolysis (95% decrease), MPC (50% increase) and PC
(520% increase). Clearly, further study of these effects is required,
but these data strongly suggest that multiple pathways are affected
and, potentially, may serve as key biomarkers of effective mTOR
inhibition.

FIGURE 10 | Dynamic glycolysis model of subcutaneous DLCL2 in a
mouse. Fitting of LacC3 in vivo data vs. time. Triangle, pretreatment, and
circle, posttreatment. Total lactate production rate, Flac = 0.80 mM/min
(pretreatment) and Flac = 0.62 mM/min (posttreatment). Clearance rates were
Fcl = 0.59 mM/min (pretreatment) and Fcl = 0.56 mM/min post-treatment
(non-steady-state condition). Rapamycin treatment affects mostly the lactate
production rate. The inset is a typical blood glucose input function used in the
model.

CONCLUSION AND SUMMARY
We have for the first time formulated and validated a detailed
metabolic network model of tumor intermediary metabolism that
includes all the key pathways except glycogen and phospholipid
metabolism as well as serine–glycine one-carbon metabolism.
These pathways can be added in the future. We have demonstrated that glutamine metabolism, while critical to AA and nucleoside/tide production, makes minimal contribution to energy
production in DB-1 melanoma. Studies of FA metabolism
have been initiated and need to be advanced further. Aerobic glycolysis and oxidative metabolism contribute approximately equally to energy production in this tumor and probably contribute in similar proportions to energy production by
many tumors, with relative contributions of glycolysis being
modulated by oxygen supply in the local environment of the
tumor.
Using NHL as a model and rapamycin as a specific therapeutic agent, we have formulated a general strategy for monitoring therapeutic response of signal transduction. This strategy
includes preliminary exploratory non-invasive 13 C MRS studies
of tumor in situ and ex vivo 13 C MRS and LC-MS studies of tumor
metabolism to identify key pathways that are modified by treatment of individual patients with specific inhibitors. Because of the
intrinsic low sensitivity of 13 C MRS, a key goal of these exploratory
studies will be to identify biomarkers of therapeutic response that

FIGURE 11 | Mass spectrometric data of intracellular metabolites.
DLCL2 tumor cells were treated with and without 200 nM rapamycin for 48 h.
Measurements were made at steady-state isotope exchange conditions
(n = 3 for each condition). *p < 0.05, **p < 0.01, ***p < 0.001.

Significant changes are evident in levels of glycolytic metabolites (glucose-6P, fructose-1,6-P, 2-phosphoglycerate, pyruvate,
and lactate), pentose shunt metabolites (6-phosphogluconate and
5-carbon phosphates), and TCA cycle (citrate, succinate, and
malate) (100, 101).
In view of the recent interest in glutamine metabolism of
tumors (71), preliminary studies were performed on DLCL2 cells
grown in culture with 4 mM [U-13 C] glutamine; after 6 h steady
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can be more readily studied by more sensitive methods, such as
1
H MRS and CEST (102) and PET/CT. In this regard, lactate
appears to be a critical metabolite that plays a central role in a
number of key metabolic pathways susceptible to modulation by
signaling inhibitors. Dynamic nuclear polarization may also play
an important role, although the short lifetime of probes, such as
13
C-labeled pyruvate, forces them to be employed at abnormally
high concentrations, which may modify the metabolic pathways
that are being monitored. Despite its intrinsically low sensitivity, 13 C MRS of glucose, lipids as well as low molecular weight
metabolites, such as acetate and glutamine, should not be ignored,
especially in view of the increasing availability of high-field instruments, such as 7 Ts, of which more than 60 are already available
at leading institutions throughout the world. These are likely to
soon gain FDA approval and will become much more useful as
body coils and other probes become more available. The recent
demonstration of the feasibility of ex vivo 13 C MRS and LC-MS
analysis of tumor specimens that have been surgically excised (18,
19) in conjunction with the current in vivo 13 C MRS study at 9.4 T
of human melanoma and lymphoma xenografts in mice point to
the feasibility of non-invasive human metabolic studies. Overall,
metabolic studies are likely to complement genomic studies of
human cancer in the near future.
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